SecBot SecBot
Biotech Drug Report Generated Oct 27, 2026

zigakibart

NVS·NOVARTIS AG
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 3
Time to market
At least 3-5 years; Phase 3 BEYOND trial estimated to complete Jan 2028, followed by regulatory filing and review.
Why 3/10
No hard dated binary catalyst (PDUFA or pivotal readout) is scheduled in the next ~12 months; the Phase 3 BEYOND trial's estimated primary completion is Aug 2027. Zigakibart is one of over 100 pipeline programs at a $200B+ diversified pharma, so even a positive readout would have limited impact on NVS shares.
Actionable Insight NEUTRAL

The next meaningful catalyst is the Phase 3 BEYOND primary completion (estimated Aug 2027) or any potential interim analysis. For a large-cap like Novartis, zigakibart alone is unlikely to drive material share-price moves. Watch for topline BEYOND results and any accelerated approval filing strategy, but this is a multi-year story within a diversified pharma portfolio.

Price Chart

Loading chart...

Executive Summary

Zigakibart is an investigational anti-APRIL monoclonal antibody in Phase 3 development by Novartis (NYSE: NVS) for IgA nephropathy (IgAN), a progressive kidney disease. It was originally developed by Chinook Therapeutics, which Novartis acquired in 2023. Phase 1/2 data showed ~60% proteinuria reduction and eGFR stabilization over 100+ weeks with a favorable safety profile. The pivotal Phase 3 BEYOND trial (NCT05852938) is active but not recruiting, with estimated primary completion in August 2027. Recent 124-week data presented at ASN Kidney Week 2026 (Oct 23) showed sustained efficacy. No BLA has been filed and no PDUFA date exists. For Novartis, a $200B+ diversified pharma with a pipeline of over 100 programs, zigakibart is a small component, and the stock is unlikely to move materially on this drug alone in the near term.

How It Works

Zigakibart is a lab-engineered antibody that blocks a signaling protein called APRIL, which is overactive in IgA nephropathy (IgAN). By neutralizing APRIL, the drug reduces the production of abnormal IgA antibodies that build up in the kidneys and cause inflammation and damage. It is given as a subcutaneous (under-the-skin) injection every two weeks.

Trial Status

The pivotal Phase 3 BEYOND study (NCT05852938, ~383 patients) is active but not recruiting, with estimated primary completion Aug 2027 and final completion Jan 2028. A Phase 3 open-label extension (NCT06858319) is recruiting. A Phase 3b combination trial with atrasentan (LUMINA IgAN, NCT07850752) is planned to start Dec 2026. Phase 1/2 data through 124 weeks were presented at ASN Kidney Week 2026.

The Two-Sided Case

▲ Bull Case4
Phase 1/2 data published in Kidney International showed zigakibart reduced proteinuria by ~60% and stabilized eGFR over 100 weeks, with a well-tolerated safety profile, a potentially disease-modifying profile in a progressive kidney disease.
124-week data presented at ASN Kidney Week 2026 (Oct 23) showed sustained proteinuria remission and durable biomarker suppression (Gd-IgA1, IgA), reinforcing the drug's long-term potential.
Novartis already has a strong IgAN franchise with Fabhalta (approved Jul 2026) and atrasentan (Vanrafia, Phase III data at ERA 2026), creating potential for combination strategies like the planned LUMINA IgAN trial of zigakibart + atrasentan.
Zigakibart targets APRIL, a distinct mechanism from complement inhibition (Fabhalta) and endothelin receptor blockade (atrasentan/Filspari), offering differentiation and potential add-on therapy use.
▼ Bear Case4
Crowded IgAN market, at least 7 FDA-approved drugs (Tarpeyo, Filspari, Fabhalta, Ultomiris, etc.) already compete, and Vertex's povetacicept has a PDUFA date of Nov 30, 2026, meaning zigakibart could enter a market with multiple entrenched options.
Phase 3 BEYOND trial won't read out until ~Aug 2027 at the earliest, so no near-term regulatory catalyst; the drug is years from potential commercialization.
As a subcutaneously injected monoclonal antibody, zigakibart faces a convenience disadvantage versus oral competitors like Tarpeyo (budesonide), Filspari (sparsentan), and Fabhalta (iptacopan).
Novartis is a $200B+ diversified pharma; zigakibart is one of over 100 pipeline programs and would need blockbuster sales to move the stock materially.

Upcoming Catalysts

  • Phase 3 BEYOND primary completion (estimated Aug 2027), topline proteinuria and eGFR data
  • LUMINA IgAN Phase 3b trial initiation (estimated Dec 2026), zigakibart + atrasentan combination study
  • Potential interim analysis of BEYOND trial (if pre-specified)
  • Any decision on accelerated approval filing strategy based on proteinuria data

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVARTIS AG 6-K NVS ·Originating report

Sources · 9

Hover a chip for the title
1 novartis.com2 clinicaltrials.gov3 novartis.com4 asn-online.org5 rarediseaseadvisor.com6 novartis.com7 trialticker.com8 adisinsight.springer.com9 medchemexpress.com